Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
DNA, RNA & Cells
Filter     Order     Display # 
Date Item Title
09 Mar 2006 StemCells, Inc. Receives IRB Approval From Oregon Health & Science University To Begin Phase I Clinical Trial In Batten Disease
07 Mar 2006 Genvec Completes Enrollment In Adpedf Clinical Study For Macular Degeneration
07 Mar 2006 Baxter Commences First-Of-Its-Kind, Phase II Adult Stem Cell Trial in U.S. In Patients With Severe Coronary Artery Disease
06 Mar 2006 Corgentech Presents Clinical Data From Phase 1/2 Trial of Avrina(TM), Drug Candidate for Eczema
04 Mar 2006 Oncolytics Biotech Inc. Phase I Combination REOLYSIN®/Radiation Clinical Trial Abstract Available on AACR Website
02 Mar 2006 Enzo Receives Approval To Commence HIV Clinical Trial
01 Mar 2006 Lorus Publishes studies on three distinct lines of research - Anticancer drug GTI-2501 and two preclinical programs
01 Mar 2006 Genasense New Drug Application Accepted for Review by FDA
01 Mar 2006 Genasense® New Drug Application Accepted for Review by FDA
25 Feb 2006 Introgen Reports Advances in Oncolytic Virus Program
24 Feb 2006 Systemic Safety Profile of Macugen(R) (pegaptanib sodium injection) Maintained Throughout Two Years with No Increased Risk of Cardiovascular Events
24 Feb 2006 Applied Genetic Technologies Corporation Announces Initiation of Phase 1 Clinical Study on Safety of AGTC-0106
23 Feb 2006 Coley Pharmaceutical Group Initiates Phase II Clinical Study of Actilon for Hepatitis C
23 Feb 2006 Corautus Genetics Announces Update on GENASIS Trial
23 Feb 2006 Genzyme Ends Enrollment in Phase 2 Trial of Cardiac Cell Therapy
22 Feb 2006 Antisoma’s AS1411 granted EU Orphan Drug Status for renal and pancreatic cancers
22 Feb 2006 Positive Results Reported From Introgen's Phase 2 Trial of INGN 225 Immunotherapy in Lung Cancer Patients
21 Feb 2006 Aldagen and Texas Heart Institute to Begin Clinical Study of Stem Cell Therapy for Advanced Heart Failure Patients
21 Feb 2006 Novartis and Alnylam Announce New Collaboration to Develop RNAi Therapeutics for Pandemic Flu
16 Feb 2006 Aegera initiates third clinical trial for aeg35156 – a targeted therapeutic for oncology
15 Feb 2006 Clinical Benefit Analysis of Genasense plus Chemotherapy Reported from Phase 3 Trial in Patients with Chronic Lymphocytic Leukemia
14 Feb 2006 Biovex begins dosing patients in phase II clinical trials of Oncovexgmcsf in malignant melanoma and in head and neck cancer
10 Feb 2006 Sangamo BioSciences Announces HIV/CCR5 ZFP Therapeutic Data Presentation at 13th Conference on Retroviruses and Opportunistic Infections
09 Feb 2006 Isis Pharmaceuticals Presents Additional Clinical Data Showing That Isis 301012 Significantly Reduces Triglycerides
08 Feb 2006 Corgentech Reports Clinical Data From Phase 1/2 Trials of Avrina(TM), Drug Candidate for Eczema
08 Feb 2006 U.S. FDA Accepts Part One of Bioniche Program for Phase III Clinical Trials with MCC for Bladder Cancer
07 Feb 2006 GenVec Macular Degeneration Study and Supporting Editorial Published in February Issue of Human Gene Therapy
07 Feb 2006 Isis Pharmaceuticals' Oral Formulation of ISIS 301012 Reduces Cholesterol in Humans
06 Feb 2006 Isis Pharmaceuticals Initiates Phase 2 Program of ISIS 301012 in Patients With Familial Hypercholesterolemia
06 Feb 2006 AnGes MG, Seikagaku to Dissolve Joint Development Agreement for NFkB Decoy-Oligo-based Intraarticular Injection
03 Feb 2006 SAP Founder Invests in Biotechnology from Baden-Wurttemberg - Germany; 22 Million Euros for Tuebingen Biotech Company CureVac
03 Feb 2006 Calando Pharmaceuticals Establishes Research Collaboration with National Cancer Institute to Develop RNAi Therapeutics; Cooperative Research and Development Agreement (CRADA) to Focus on RNAi Therapeutics -- to Target Neuroblastoma
03 Feb 2006 Acuity Completes Patient Enrollment in Phase II Trial in Wet AMD and Initiates New Trial in Diabetic Macular Edema
03 Feb 2006 Analysis of Genasense® Trial Confirms Major Efficacy Variables in Patients with Advanced Melanoma
03 Feb 2006 OSI Pharmaceuticals Announces European Regulatory Approval for Macugen(R) (pegaptanib sodium injection); First Treatment for Neovascular (Wet) Age-related Macular Degeneration (AMD) That Targets Underlying Disease Process
02 Feb 2006 Genasense® Marketing Authorization Application in Melanoma Accepted for Review by European Regulatory Agency
01 Feb 2006 Lilly Initiates Clinical Trials on Second Cancer Drug Discovered in Isis Collaboration
01 Feb 2006 Benitec Delays IND Filing for HIV/AIDS Therapeutic Pending Resolution Of Manufacturing Result
31 Jan 2006 Gentium's Defibrotide Subject of Independent Study in Japan; First Japanese Study Reports That Defibrotide Shows Success Treating Severe Veno-Occlusive Disease
27 Jan 2006 Long-Term Survival Data from Genvec's Phase II Study of TNFerade(TM) in Esophageal Cancer Presented at ASCO GI; Survival Profile Compares Favorably with Recent Studies
27 Jan 2006 Corautus Genetics' Phase IIb Clinical Trial for Severe Angina Treatment Receives Go-Ahead from Data Safety Monitoring Committee Based on Final Scheduled Interim Safety Data Review
26 Jan 2006 Sangamo BioSciences Announces Publication of ZFP Therapeutic(TM) Data for Peripheral Artery Disease Program
25 Jan 2006 Targeted genetics announces strategic restructuring to reduce expenses and advance lead inflammatory arthritis product candidate
25 Jan 2006 Subcutaneous Genasense® Trial Initiated in Patients with Solid Tumors
 
<< Start < Prev 11 12 Next > End >>
Results 551 - 594 of 594

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Emerging Diabetes Drugs

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics